Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).

被引：0
|
作者：
Chang, Lawrence
Hall, Peter S.
Preger, Luciana
Sjekloca, Nikoleta
Bergamaco, Estevan
Broe, Anne
Petrova, Plamena
Berg, Paul
Reich, Adam
Pawar, Neha
Gharaibeh, Mahdi
机构：
[1] Gilead Sci Inc, Foster City, CA USA
[2] Univ Edinburgh, Inst Genet & Canc, Edinburgh, Scotland
[3] Genentech Inc, South San Francisco, CA USA
[4] IQVIA, London, England
[5] IQVIA, Sofia, Bulgaria
[6] IQVIA, La Crosse, WI USA
[7] IQVIA, Gurgaon, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1075
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) immuno-oncology (IO) monotherapy (mono tx)
    Talbot, D.
    Fish, S. M.
    Ong, T. Jin
    Flick, E. D.
    Waterhouse, D. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH METASTATIC UROTHELIAL CANCER RECEIVING SECOND-LINE THERAPY IN THE US VETERAN POPULATION
    Bhanegaonkar, A.
    Kim, R.
    Pandya, S.
    Krulewicz, S.
    Wang, L.
    Pennock, G.
    Phatak, H.
    VALUE IN HEALTH, 2019, 22 : S390 - S390
  • [33] Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) in the first-line (1L)
    Paluri, Ravi Kumar
    Silver, Michelle
    Cockrum, Paul
    Dennen, Syvart
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer
    Haiderali, Amin
    Rhodes, Whitney C.
    Gautam, Santosh
    Huang, Min
    Sieluk, Jan
    Skinner, Karen E.
    Schwartzberg, Lee S.
    FUTURE ONCOLOGY, 2021, 17 (29) : 3819 - 3831
  • [35] Second-line chemotherapy (2L) in elderly patients with advanced biliary tract cancer (ABC): A multicenter real-world study.
    Rizzo, Alessandro
    Salati, Massimiliano
    Frega, Giorgio
    Merz, Valeria
    Caputo, Francesco
    Ricci, Angela Dalia
    Palloni, Andrea
    Messina, Carlo
    Spallanzani, Andrea
    Saccoccio, Gioconda
    Mollica, Veronica
    Gelsomino, Fabio
    Benatti, Stefania
    Luppi, Gabriele
    Melisi, Davide
    Dominici, Massimo
    Brandi, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [36] Real-world analysis of taxane use in the first-line setting and prior comorbidities among female metastatic triple-negative breast cancer patients
    Lin, Shih-Wen
    Thakrar, Dixa
    Simpson, Joseph
    Funke, Roel
    Chui, Stephen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 97 - 98
  • [37] A real world multicenter study of first (1L) and second (2L) line treatment patterns and outcomes in advanced pancreatic cancer (APC).
    Cheung, Winson Y.
    Zhang, Hanbo
    Tang, Patricia A.
    Spratlin, Jennifer L.
    Lee-Ying, Richard M.
    Goodwin, Rachel Anne
    Meyers, Brandon Matthew
    Armstrong, Dawn Elizabeth
    Ramjeesingh, Ravi
    Vickers, Michael M.
    Kim, Christina
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis
    Carey, Lisa A.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Dieras, Veronique
    Dalenc, Florence
    Diamond, Jennifer R.
    Fontaine, Christel
    Wang, Grace
    Rugo, Hope S.
    Hurvitz, Sara A.
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Loibl, Sibylle
    Gianni, Luca
    Piccart, Martine
    Zhu, Yanni
    Delaney, Rosemary
    Phan, See
    Cortes, Javier
    NPJ BREAST CANCER, 2022, 8 (01)
  • [39] Real-world analysis of irinotecan (iri) with or without fluorouracil (5FU) in the second line treatment (2L) of metastatic colorectal cancer (mCRC)
    Lentz, Robert William
    Hu, Junxiao
    Robinson, Hannah Ruth
    Balmaceda, Nicole Baranda
    Ebot, Emily Eyoung Baiyee
    Leal, Alexis Diane
    Kim, Sunnie S.
    Davis, S. Lindsey
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 102 - 102
  • [40] Treatment patterns and characteristics in the second and third-line therapy setting for real-world small cell lung cancer patients.
    Prince, Patricia
    Estrin, Adina
    Supina, Dylan
    Ben-Joseph, Rami
    Boccuti, Anne
    Asubonteng, Kobby
    Rengarajan, Badri
    Fridman, Moshe
    Hanvesakul, Raj
    Taylor, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345